Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cybin ( (HELP) ) has issued an update.
Helus Pharma has appointed veteran biopharma executive Michael Cola as chief executive officer, marking a strategic shift as the company moves from early clinical work to later-stage development and commercialization planning for its mental health therapies. Cola’s arrival coincides with key upcoming catalysts, including Phase 2 data for HLP004 this quarter and Phase 3 topline results for HLP003 expected in the fourth quarter of 2026.
With more than three decades of experience in neuroscience, rare disease, and specialty pharmaceuticals, Cola brings a track record of scaling CNS franchises at Shire, Astra-Merck, and AstraZeneca, as well as leading Avalo Therapeutics and serving in senior board roles. His appointment is intended to strengthen Helus’s leadership in global regulatory engagement, capital formation, and commercial execution as it seeks to translate its clinical pipeline and extensive IP estate into long-term value for patients and shareholders.
The most recent analyst rating on (HELP) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Cybin stock, see the HELP Stock Forecast page.
More about Cybin
Helus Pharma is a Boston- and Toronto-based clinical-stage pharmaceutical company focused on developing novel serotonergic agonists for serious mental health disorders. Listed on Nasdaq and Cboe Canada under the symbol HELP, the company is building a broad intellectual property portfolio with more than 350 global patent applications and over 100 granted patents to support its multi-asset CNS pipeline.
Average Trading Volume: 661,693
Technical Sentiment Signal: Sell
Current Market Cap: $1.41M
For an in-depth examination of HELP stock, go to TipRanks’ Overview page.